Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 7, 2007
Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurementAndre Willasch, Gaby Schneider, Britta Sofia Reincke, et al.Cytotherapy|October 7, 2011
The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cellsEva Rettinger, Selim Kuçi, Ivonne Naumann, et al.British Journal of Haematology|February 24, 2005
Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapyPeter Bader, Charlotte Niemeyer, Andre Willasch, et al.Haematologica|April 10, 2010
Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantationSelim Kuçi, Eva Rettinger, Bernhard Voss, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2016
Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after TransplantationEva Rettinger, Michael Merker, Emilia Salzmann-Manrique, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2019
Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte InfusionsMichael Merker, Emilia Salzmann-Manrique, Verena Katzki, et al.British Journal of Haematology|March 23, 2023
Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donorsAndrea Jarisch, Emilia Salzmann-Manrique, Jan Soerensen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study GroupPeter Bader, Hermann Kreyenberg, Günter H R Henze, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignanciesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.Pageof 3